MiRNA modulators of thermogenesis
Provided are novel methods and compositions for the modulation of thermogenesis. Such methods are particularly advantageous in that they allow for the reduction of body fat in a subject without the subject having to adjust their caloric intake through dieting, modify their physical activity or undergo bariatric surgery. Accordingly, the methods of the invention are particularly useful for treating or preventing obesity. Also provided are methods of screening for novel agents that modulate the activity of thermogenic regulators.
1. A method for treating diabetes mellitus in a subject, the method comprising administering to the subject an effective amount of an antagomir of miR-22, miR-22-3p or miR-22-5p.
2. The method of claim 1 , wherein the human subject selected for treatment is overweight or obese or has a genetic or epigenetic predisposition to obesity.
3. The method of claim 1 , wherein the antagomir modulates the activity or expression of UCP1 or UCP2.
4. The method of claim 1 , wherein the antagomir comprises an antagomir of miR-22-3p.
5. The method of claim 1 , wherein the antagomir is linked to a targeting moiety or mixed with a liposome or nanoparticle.
6. The method of claim 5 , wherein the targeting moiety is an aptamer.
7. The method of claim 5 , wherein the targeting moiety delivers the miRNA agent to a specific cell type, organ or tissue.
8. The method of claim 1 , wherein the miRNA agent directly binds to the mRNA or promoter region of at least one mitochondrial uncoupler.
9. The method of claim 1 , wherein the miRNA agent directly binds to the 5′UTR or coding sequence of the mRNA of at least one mitochondrial uncoupler.
10. The method of claim 1 , wherein the miRNA agent modulates the activity of an activator or repressor of a mitochondrial uncoupling protein.
11. The method of claim 1 , wherein the mRNA or protein expression of the mitochondrial uncoupling protein is upregulated.
12. The method of claim 1 , wherein the mitochondrial uncoupling activity of the mitochondrial uncoupling protein is upregulated.
13. The method of claim 1 , wherein the subject is a mammal.
14. The method of claim 13 , wherein the mammal is a human.
15. The method of claim 1 , wherein the diabetes comprises type 2 diabetes mellitus.
16. The method of claim 15 , wherein the type 2 diabetes mellitus is early onset type 2 diabetes mellitus.